Mainz Biomed B.V. Stock (NASDAQ:MYNZ)
Previous Close
$0.83
52W Range
$0.55 - $5.34
50D Avg
$0.99
200D Avg
$1.41
Market Cap
$3.45M
Avg Vol (3M)
$574.01K
Beta
0.32
Div Yield
-
MYNZ Company Profile
Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.